Independent
Tenure on this board
2.2 yrs
2 nominees · 5 ballot items.
Five proposals are being voted on at Onconetix, Inc.'s annual meeting: Director Election Proposal; Series D PIPE Proposal; Series E PIPE Proposal; Auditor Ratification Proposal; and Adjournment Proposal. The Board recommends voting FOR each proposal.
Re-elect Thomas Meier and elect Sarah Romano to Class I directors of the Company for a three-year term expiring at the 2028 annual meeting.
To approve the issuance of up to 4,424,080 shares of Common Stock upon conversion of Series D Preferred Stock and up to 4,362,827 shares upon exercise of Series D Warrants, issued in a private placement, and related matters under Nasdaq Rule 5635.
To approve the issuance of up to 2,025,223 shares of Common Stock upon conversion of Series E Preferred Stock and up to 2,025,223 shares upon exercise of Series E Warrants, issued in a private placement, and related matters under Nasdaq Rule 5635.
To ratify the appointment of MaloneBailey, LLP as Onconetix, Inc.’s independent registered public accounting firm for the fiscal year ending December 31, 2025.
To approve the adjournment of the Annual Meeting to solicit additional proxies if there are insufficient votes to approve the foregoing proposals.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | GEODE CAPITAL MANAGEMENT, LLC | 1.02% | 11,720 | $17K |
| 2 | CITIGROUP INC | 0.15% | 1,717 | $3K |
| 3 | UBS Group AG | 0.14% | 1,580 | $2K |
| 4 | Tower Research Capital LLC (TRC | 0.13% | 1,454 | $2K |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 0.01% | 134 | $199 |
| 6 | SBI Securities Co., Ltd. | 0.01% | 120 | $179 |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.